EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more EDAP TMS Charts. Click Here for more EDAP TMS Charts.](/p.php?pid=staticchart&s=N%5EEDAP&p=8&t=15)
EDAP TMS Follows Up on the Success of HIFU With Ablatherm at
Recent International Congresses
VAULX-EN-VELIN, France, Oct. 7 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), a global leader in the development, marketing and distribution
of a portfolio of minimally-invasive medical devices for the treatment of
urological diseases, today follows up on its recent participation in two major
international congresses in Japan and Germany.
The 4th International Society for Therapeutic Ultrasound (ISTU) held in Kyoto,
Japan, on September 18-20, 2004 was a great success. The growing interest for
HIFU technology applied to the medical field reinforces the need for such
International Society whose objectives are to encourage research on therapeutic
ultrasound and promote international scientific and industrial cooperation.
Many presentations were made on the use of therapeutic ultrasound to treat
various tumors from kidney tumors to breast's, heart's, liver's, prostate's,
etc ... The ISTU Symposium confirmed the leadership of Ablatherm as the first
and most advanced approved product using High Intensity Focused therapeutic
Ultrasound to treat localized prostate cancer. Dr. Gelet, from Edouard Herriot
hospital, Lyon, France, presented his successful clinical results over 10 years
using HIFU with Ablatherm and Dr. Thuroff, from Harlaching Hospital, Munich,
Germany, shared his long experience of HIFU technology. Our Research Partner,
INSERM, also presented its development programs, still experimental, on the
application of therapeutic ultrasound to kidney tumors.
Mr. Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "We can
really observe the growing interest from the Scientific and Medical communities
for this technology. Therapeutic ultrasound opens a new era of
minimally-invasive treatments addressing various cancer indications at a lower
medical cost."
EDAP also participated in the 56th Congress of the German Society for Urology
(D.G.U.: Deutsche Gesellschaft fur Urologie) held in Wiesbaden, Germany, on
September 22-25, 2004. More than 3,000 Urologists attended the Congress where
EDAP's "Meet the Experts" workshop achieved a real success. Ablatherm users
were all very keen on sharing openly their HIFU experience with doctors coming
to enquire about HIFU with Ablatherm applied to localized prostate tumors.
Judith Johannsen, General Manager of EDAP Germany, commented: "We are very
enthusiastic about this growing interest for HIFU in Germany. We can tell that
HIFU with Ablatherm made a real breakthrough at this year's DGU, which was
confirmed by a larger number of Urologists coming to get information about this
new treatment. Many of these physicians have had a positive feedback from their
patients treated with HIFU and were enquiring about sharing an Ablatherm on a
mobile basis."
Mr. Hugues de Bantel, Chief Executive Officer of EDAP TMS, concluded: "We see a
clear progress of our Ablatherm business in the third largest single market
after the U.S.A. and Japan and we look forward to reporting to you about this
breakthrough during our Third Quarter conference call, to be held on October
28, 2004."
EDAP TMS will also be participating in two upcoming congresses:
- The "World Congress of Endourology" (W.C.E.) on November 3-6, 2004 to
be held in Mumbai, India (booths # 113 & 114),
- The "Association Francaise d'Urologie" (A.F.U.) on November 17-20, 2004
to be held in Paris, France (booth # F40).
EDAP TMS S.A. is the global leader in the development, production, marketing
and distribution of a portfolio of minimally invasive medical devices primarily
for the treatment of urological diseases. The Company currently develops and
markets devices for the minimally invasive treatment of localized prostate
cancer, using High Intensity Focused Ultrasound (HIFU), through its EDAP SA
subsidiary; it is also developing this technology for the treatment of certain
other types of tumors. EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL), via its TMS SA subsidiary. In addition, the Company markets
in Japan and Italy devices for the non-surgical treatment of benign Prostate
Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). For more information,
contact the Investor Relations Department by phone at +33 (0)4 78 26 40 46. For
additional information on the Company, please see the Company's web site at:
http://www.edap-tms.com/.
This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission.
CONTACT: Hugues de Bantel - Philippe Chauveau - Blandine Confort
+33 4 78 26 40 46
DATASOURCE: EDAP TMS S.A.
CONTACT: Hugues de Bantel, Philippe Chauveau or Blandine Confort, all of
EDAP TMS S.A., +33-4-78-26-40-46
Web site: http://www.edap-tms.com/